title: Effect of mometasone furoate on early and late phase inflammation in patients with seasonal allergic rhinitis.
abstract: BACKGROUND
  Mometasone furoate is a potent glucocorticoid that can markedly inhibit proinflammatory Th2 cytokines in vitro. An aqueous nasal spray formulation has been shown to be clinically active in reducing the symptoms of perennial and seasonal allergic rhinitis.
  
  
  OBJECTIVE
  To determine whether pretreatment with mometasone furoate 200 microg once daily decreases specific indices of early and late phase nasal inflammation compared with placebo.
  
  
  METHODS
  A randomized, double-blind, placebo-controlled crossover study was conducted using nasal provocation with ragweed antigen in 21 patients with ragweed-induced allergic rhinitis out of the ragweed season; the treatment period was 2 weeks. Symptom scores, rhinoprobe cytology, and nasal lavage fluid were collected during early and late phase periods for nasal cytokines (interleukin, 1, 4, 5, 6, and 8) and leukotriene B4 determinations using ELISA and RIA.
  
  
  RESULTS
  Mean nasal symptom scores and sneezing frequency were consistently lower with mometasone furoate compared with placebo. Treatment was associated with a statistically significant early phase (30-minute time point) reduction in nasal lavage histamine levels compared with placebo (14.3 versus 20.2 ng/mL, P = .02). Within-treatment comparisons suggested that mometasone furoate reduced the antigen-induced late-phase response for IL-6, IL-8, and eosinophils compared with pretreatment. There were similar, but smaller, changes seen in the placebo group for these measurements. There were no statistically significant changes following antigen challenge in IL-1, IL-4, IL-5, LTB4, or in other nasal cytology parameters.
  
  
  CONCLUSIONS
  These results suggest that the clinical activity of mometasone furoate nasal spray in seasonal allergic rhinitis is likely due, in part, to a reduction in the levels of histamine in nasal secretions related to the early phase response, and reductions in IL-6, IL-8, and eosinophils during the late phase response.
authors.affiliation: Department of Medicine, Nassau County Medical Center, East Meadow, New York 11554, USA.
authors.forename: M
authors.initials: M
authors.lastname: Frieri
authors.forename: J
authors.initials: J
authors.lastname: Therattil
authors.forename: V
authors.initials: V
authors.lastname: Chavarria
authors.forename: J
authors.initials: J
authors.lastname: Cosachov
authors.forename: N S
authors.initials: NS
authors.lastname: Kumar
authors.forename: S F
authors.initials: SF
authors.lastname: Wang
authors.forename: G
authors.initials: G
authors.lastname: Sansone
authors.forename: J
authors.initials: J
authors.lastname: Etzel
authors.forename: D
authors.initials: D
authors.lastname: Dellevecchia
authors.forename: M
authors.initials: M
authors.lastname: Zitt
authors.forename: B
authors.initials: B
authors.lastname: Mesarina-Wicki
authors.forename: K B
authors.initials: KB
authors.lastname: Nolop
mesh_terms: D000328:Adult; D018926:Anti-Allergic Agents / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D018592:Cross-Over Studies; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000068656:Mometasone Furoate; D009297:Nasal Mucosa / Q000737:chemistry / Q000166:cytology; D009299:Nasal Provocation Tests; D011244:Pregnadienediols / Q000627:therapeutic use*; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy*; D012912:Sneezing / Q000187:drug effects; D013997:Time Factors
chemical_list: D018926:Anti-Allergic Agents; D000893:Anti-Inflammatory Agents; D011244:Pregnadienediols; D000068656:Mometasone Furoate